C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/22 (2006.01) C12N 5/16 (2006.01) C12N 15/13 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2691378
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells. The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
La présente invention porte sur des compositions et des procédés permettant de caractériser, de diagnostiquer et de traiter un cancer. En particulier, la présente invention permet d'identifier LGR5 en tant que protéine surexprimée dans une cellule souche de tumeur solide. La présente invention permet en outre d'identifier une interaction entre RSPO1 et LGR5 en tant que voie alternative pour l'activation de la signalisation de la bêta-caténine. Dans certains modes de réalisation, la présente invention porte sur des biomolécules qui interrompent la signalisation fonctionnelle par l'intermédiaire d'une protéine LGR, comprenant, dans certains modes de réalisation, des molécules qui inhibent l'interaction entre une ou plusieurs protéines RSPO et une ou plusieurs protéines LGR, telles que LGR5. Dans certains modes de réalisation, la présente invention porte sur des procédés de traitement du cancer comprenant l'interruption de la signalisation LGR fonctionnelle et l'inhibition de la croissance d'une tumeur solide comprenant des cellules souches de tumeur solide.
Mbm Intellectual Property Law Llp
Oncomed Pharmaceuticals Inc.
LandOfFree
Compositions and methods for treating and diagnosing cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating and diagnosing cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating and diagnosing cancer will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2031231